(fifthQuint)Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis.

 Participants received intramuscular injections of palivizumab according to physicians' prescription and the local label.

 The local label recommended 1 month injection intervals between 5 sequential injections at a dose of 15 mg/kg.

 Participants could have received from 3 to 5 monthly injections of palivizumab during the 2014 - 2015 RSV season and the duration of this study.

.

 Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis@highlight

This was a non-interventional, prospective, multi-center study with no control group designed to assess the effectiveness of palivizumab in a population of infants at high-risk of serious Respiratory Syncytial Virus (RSV) illness (infants born 35 weeks of gestation and infants 24 months with Bronchopulmonary Dysplasia (BPD) or Congenital Heart Disease (CHD)).

 Participants received immunoprophylaxis during the RSV season, defined as October 2014 through April 2015, in routine clinical settings throughout the Russian Federation.

